[Co-operative study of all-trans retinoic acid as a differentiation induction therapy of acute promyelocytic leukemia].
Efficacy and safety of tretinoin (all-trans retinoic acid, ATRA, Ro01-5488) for refractory and relapsed acute promyelocytic leukemia were studied by multi-institutional study in Japan. 22 out of 27 (81.5%) patients with previously untreated who were intolerable to chemotherapy, relapsed and refractory were achieved CR. And 4 out of 11 (36.4%) in relapsed patients who received ATRA remission induction therapy previously responded. Side effects, such as dryness of the lip and skin, headache, increase of triglyceride, beta-lipoprotein and lactate dehydrogenase, were observed in 36 of 41 eligible patients (87.8%) but these were well tolerated. In addition to these, hyperleukocytosis in 4 cases and retinoic acid syndrome in 3 cases were observed. However, all patients were prescribed tretinoin again by adequate management.
Yamada
O
O
Dept. of Medicine, Kawasaki Medical School.
Hatake
K
K
Tanimoto
M
M
Ishiyama
T
T
Ohno
R
R
Shirakawa
S
S
Horiuchi
A
A
Tomonaga
M
M
Ohta
K
K
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002214:Capsules; D002454:Cell Differentiation / Q000187:drug effects; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D002214:Capsules; D008055:Lipids; D014212:Tretinoin